Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05130515 | Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. | PHASE2 | COMPLETED | 6 | — | — | Dec 15, 2021 | Jan 1, 2023 | Jan 31, 2023 | 1 | China |
The primary objective of this study is to determine the preliminary efficacy of administration of niraparib in combination with anlotinib in the treatment of platinum-resistant recurrent or platinum-refractory clear cell ovarian cancer, as measured by the objective response rate (ORR), which is a combination of CR (complete response, the target lesion completely disappeared over 4 weeks) and PR (partial response, the target lesions were reduced by more than 30% for more than 4 weeks).
| Arm | Type | Description |
|---|---|---|
| Treatment group | EXPERIMENTAL | Niraparib 200mg po QD day1\~21, Anlotinib 10mg po QD day1\~14 |
| Name | Type | Description |
|---|---|---|
| Niraparib | DRUG | Niraparib 200mg po QD, day1\~21 |
| Anlotinib | DRUG | Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle |
Inclusion Criteria: 1. The patients understood the test process, signed the informed consent form and agreed to participate in the study. 2. 18 \~70 years old, female. 3. Histologically confirmed ovarian clear cell carcinoma. 4. The patients received platinum-based chemotherapy after primary debulk...